Actinium Net Income From Continuing Ops from 2010 to 2026
| ATNM Stock | USD 1.11 0.01 0.89% |
Net Loss | First Reported 2012-03-31 | Previous Quarter -6.9 M | Current Value -5.1 M | Quarterly Volatility 11.3 M |
Check Actinium Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Actinium Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 1.3 M, Selling General Administrative of 14.6 M or Other Operating Expenses of 50.9 M, as well as many indicators such as Price To Sales Ratio of 1.6 K, Dividend Yield of 0.0 or PTB Ratio of 1.09. Actinium financial statements analysis is a perfect complement when working with Actinium Pharmaceuticals Valuation or Volatility modules.
Actinium | Net Income From Continuing Ops | Build AI portfolio with Actinium Stock |
Evaluating Actinium Pharmaceuticals's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Actinium Pharmaceuticals's fundamental strength.
Latest Actinium Pharmaceuticals' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Actinium Pharmaceuticals over the last few years. It is Actinium Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Actinium Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Actinium Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (24,954,841) | |
| Coefficient Of Variation | (44.04) | |
| Mean Deviation | 8,097,826 | |
| Median | (24,321,724) | |
| Standard Deviation | 10,989,150 | |
| Sample Variance | 120.8T | |
| Range | 39.4M | |
| R-Value | (0.86) | |
| Mean Square Error | 33T | |
| R-Squared | 0.74 | |
| Slope | (1,876,816) | |
| Total Sum of Squares | 1932.2T |
Actinium Net Income From Continuing Ops History
About Actinium Pharmaceuticals Financial Statements
Actinium Pharmaceuticals investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Actinium Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -34.4 M | -36.1 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Actinium Pharmaceuticals Correlation against competitors. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Will Biotechnology sector continue expanding? Could Actinium diversify its offerings? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Actinium Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.11) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Actinium Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Actinium's accounting equity. The concept of intrinsic value - what Actinium Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Actinium Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that Actinium Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Actinium Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Actinium Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.